We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

88 hedge funds and large institutions have $1.77B invested in China Biologic Products Holdings, Inc. in 2019 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 9

25% more capital invested

Capital invested by funds: $1.42B → $1.77B (+$352M)

24% more funds holding

Funds holding: 7188 (+17)

8% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 25

29% less call options, than puts

Call options by funds: $22.8M | Put options by funds: $32.2M

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

Holders
88
Holders Change
+17
Holders Change %
+23.94%
% of All Funds
1.93%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.09%
New
26
Increased
23
Reduced
25
Closed
9
Calls
$22.8M
Puts
$32.2M
Net Calls
-$9.45M
Net Calls Change
-$19.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Capital Research Global Investors
1
Capital Research Global Investors
California
$481M +$83.8M +842,441 +25%
HA
2
HHLR Advisors
Cayman Islands
$315M
YCMGA
3
York Capital Management Global Advisors
New York
$120M -$7.68M -77,279 -7%
Temasek Holdings
4
Temasek Holdings
Singapore
$113M
Vanguard Group
5
Vanguard Group
Pennsylvania
$103M -$4.95M -49,751 -5%
HSBC Holdings
6
HSBC Holdings
United Kingdom
$99.8M -$23.4M -234,939 -21%
Bank of America
7
Bank of America
North Carolina
$96.3M +$1.5M +15,037 +2%
BlackRock
8
BlackRock
New York
$48.2M +$2.83M +28,478 +7%
Fidelity International
9
Fidelity International
Bermuda
$47.5M -$12.8K -129 -0%
Norges Bank
10
Norges Bank
Norway
$46.2M
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$32.6M +$17.2M +173,130 +155%
GAM
12
Greenwoods Asset Management
Cayman Islands
$27.4M -$23.8M -239,790 -50%
MCP
13
Maso Capital Partners
Hong Kong
$25.6M +$7.2M +72,366 +48%
AII
14
AGF Investments Inc
Ontario, Canada
$24.6M +$21.4M +215,088 New
Fidelity Investments
15
Fidelity Investments
Massachusetts
$17.4M -$15M -151,269 -50%
NAMA
16
Nikko Asset Management Americas
New York
$14.8M +$1.97M +19,846 +18%
Canada Pension Plan Investment Board
17
Canada Pension Plan Investment Board
Ontario, Canada
$10.5M
PCM
18
Pentwater Capital Management
Florida
$9.56M +$8.3M +83,490 New
OAM
19
Oxford Asset Management
United Kingdom
$8.22M +$7.14M +71,815 New
Group One Trading
20
Group One Trading
Illinois
$8.01M +$5.56M +55,908 +397%
Mirae Asset Global Investments
21
Mirae Asset Global Investments
South Korea
$7.8M +$6.77M +68,141 New
Man Group
22
Man Group
United Kingdom
$7.45M +$6.47M +65,092 New
Marshall Wace
23
Marshall Wace
United Kingdom
$7.41M +$6.44M +64,760 New
Legal & General Group
24
Legal & General Group
United Kingdom
$6.96M +$5.82M +58,487 +2,481%
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$6.21M +$1.08M +10,813 +25%

CBPO Hedge Fund Activity: Q3 2019 in Review

88 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q3 2019, worth a combined $1.77B — up 25% from $1.42B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new CBPO positions and 9 closed out — a net gain of 17 holders — while 23 added to existing stakes and 25 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $83.8M. The largest seller was Capital World Investors, exiting entirely with an estimated $32.7M sold.

  • 88 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q3 2019, up from 71 in Q2 2019.
  • Funds reported $1.77B of China Biologic Products Holdings, Inc. stock for Q3 2019, up 25% quarter-over-quarter.
  • 26 funds opened new China Biologic Products Holdings, Inc. positions in Q3 2019 and 9 closed out, a net change of +17 holders.
  • The largest China Biologic Products Holdings, Inc. buyer in Q3 2019 was Capital Research Global Investors, an estimated $83.8M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q3 2019 was Capital World Investors, an estimated $32.7M sold.

Based on aggregated 13F filings for Q3 2019.